×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: cancer | drug | novartis | brain | childhood | tafinlar | mekinist

FDA Approves Novartis Targeted Cancer Drug Against Brain Tumors

diagnosis pad with 'brain cancer' written in, stethoscope, pills
(Dreamstime)

Thursday, 23 June 2022 07:16 AM

A targeted oral drug combination by Novartis won U.S. approval for use in a wide range of advanced solid tumors that are driven by a certain genetic contributor, widening the use of a novel treatment approach that is known as tumor agnostic.

The Food and Drug Administration early on Thursday granted accelerated approval for the combination of the two drugs Tafinlar and Mekinist for adults and children as young as six with inoperable or metastatic solid tumors with a mutation known as BRAF V600, who have exhausted other treatment options.

The approval may be changed or withdrawn, depending on the results of later confirmatory trials, the Swiss drugmaker said in a statement.

Earlier this month, the oral drug combination showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial.

The participants in that trial, aged 1 to 17 years, were suffering from low-grade gliomas (LGG), the most common childhood brain cancer. Here too, the trial only included those who were found to have the BRAF V600 mutation, a genetic contributor in about 15% to 20% of pediatric LGG cases. Tafinlar and Mekinist, a pill combination with $1.7 billion in 2021 sales, up 10%, had previously won approvals to treat certain skin, lung and thyroid cancer patients who have the BRAF V600 genetic change.

The treatment is an important growth driver in Novartis's oncology business, a key therapeutic area for the Swiss group, which relies on drug development as it considers the sale of its Sandoz business with off-patent generic drugs.

Other tumor agnostic drugs, which are typically used on solid tumors regardless of where in the body they started, are Bayer's Vitrakvi and Roche's Rozlytrek, which target the TRK mutation, a genetic driver in less than 1% of cancers. Due to its rarity it often goes untested.

Bayer has said it was struggling to encourage physicians to diagnose patients that qualify for the niche drug.

© 2022 Thomson/Reuters. All rights reserved.


Health-News
A targeted oral drug combination by Novartis won U.S. approval for use in a wide range of advanced solid tumors that are driven by a certain genetic contributor, widening the use of a novel treatment approach that is known as tumor agnostic.
cancer, drug, novartis, brain, childhood, tafinlar, mekinist, braf v600, glioma
323
2022-16-23
Thursday, 23 June 2022 07:16 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved